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Consultations have been held to promote the revision of the WHO guidelines for assuring the quality and nonclinical safety
evaluation of DNA vaccines adopted by the Expert Committee on Biological Standardization (ECBS) in 2005. The drivers for this
revision are described, including the need for regulatory convergence highlighted by the WHO R&D Blueprint. These consultations
have driven the revision to its current form, where a new guideline that includes quality, nonclinical, and clinical evaluation of
plasmid DNA vaccines is being prepared for public consultation with a view to present to an upcoming ECBS. Major changes to the
guidelines include streamlining the existing quality (part A) and nonclinical (part B) sections to reflect the two decades of
experience, with manufacturing and control, nonclinical evaluation, and clinical testing of plasmid DNA vaccines, as a platform
technology. The urgency for gaining regulatory convergence on this topic is that development of such a platform technology as
DNA vaccines for routine use immunizations will prepare manufacturers and regulators across the globe in dealing with rapid
development of medical countermeasures against emerging infectious diseases even in the face of an emergency setting. Two
examples are described of Zika candidate vaccines that have rapidly advanced in development based on preexisting nonclinical
and clinical data that precluded the need to repeat nonclinical toxicology. This report describes the progress stemming from the
most recent consultation on the guidelines, including topics discussed and consensus reached.
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INTRODUCTION
Promoting regulatory convergence is recognized as a key enabler
in the World Health Organization (WHO) R&D Blueprint. Regulatory
preparedness for public health emergencies (PHEs) was on the
agenda of the 17th International Conference of Drug Regulatory
Authorities (ICDRA) meeting in 2016. A number of regulatory gaps
were identified and ICDRA recommended WHO should ensure
that regulatory support is a priority area of activity as the R&D
Blueprint for emerging infectious diseases is implemented1. It was
also requested WHO should continue developing measurement
and written standards that serve as a basis for regulatory
evaluation taking into consideration: (1) priority pathogens
defined by the Blueprint, and (2) a more flexible and dynamic
approach to developing and establishing standards for quality,
safety, and efficacy of products for use in PHEs2.
In response to the request, WHO convened an informal
consultation in February 2018 to initiate the work to revise the
guidelines for assuring the quality and nonclinical safety evalua-
tion of DNA vaccines (Annex 1, WHO Technical Report Series No.
941) adopted by the 2005 ECBS3. Based on the agreement in the
informal consultation in February 2018, the first revised draft was
prepared by a drafting group and posted on WHO Biologicals
website for the first round of public consultation (https://www.
who.int/biologicals/WHO_DNA_vaccine_HK_26_July_2019.pdf).
The consultation in December 2019 aimed to discuss and obtain
advice on the first draft document and main issues addressed
from the public consultation.
About 35 experts participated in the consultation, including the
regulators from 13 countries in six WHO regions.
Dr. Heidi Meyer (Paul-Ehrlich-Institut, Germany) was nominated
as chairperson and Dr. Rebecca Sheets (WHO consultant, USA) as
rapporteur for the consultation.
Dr Ivana Knezevic (WHO HQ, Switzerland) welcomed all the
participants to Geneva and briefed the participants on the
activities of WHO in the area of biological standardization. She
explained that WHO is the directing and coordinating authority for
health on behalf of the 194 member countries in the United
Nations system. In order to fulfill WHO objectives, a core WHO
function defined as setting norms and standards, and promoting
and monitoring their implementation has been conducted for
70 years. This initiative includes assisting National Regulatory
Authorities (NRAs) in the utilization of WHO Biological Reference
Materials and application of the principles in WHO guidelines and
recommendations, to ensure quality, safety and efficacy of
vaccines, and other biologicals.
The world of immunization is a rapidly evolving field, and is
constantly changing the picture of morbidity and mortality of
infectious diseases. In that context, vaccines are playing a critical
role in disease prevention and access to vaccines of assured
quality is one of the goals of the WHO. At the same time, the use
of new technologies for manufacturing, as well as new antigens,
adjuvants, and routes of administration are imposing lots of
challenges not only to regulators, but also to public health
professionals. In addition, the response to PHEs, such as Ebola and
Zika outbreaks triggered development of a number of vaccine
candidates based on nucleic acid platforms. Clinical trials with
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these candidates for different diseases are either ongoing or
planned in the near future (post meeting note: at the time of the
submission of this paper for publication, more than ten vaccine
candidates against the coronavirus disease (COVID-19), based on
nucleic acids, are being developed. WHO is monitoring vaccines
under development continuously and provides regular updates
on it (https://www.who.int/blueprint/priority-diseases/key-action/
novel-coronavirus/en/). This is increasing the importance of the
revision and update of WHO guidelines for evaluation of DNA
vaccines in line with the scientific advances.
Furthermore, WHO has other initiatives that are closely linked to
the standardization of vaccines. In particular, strengthening of
NRAs is one of the important elements in assuring the quality of
vaccines worldwide. Prequalification of vaccines by WHO is an
important mechanism through which vaccines become subject of
supply by UNICEF. Safety of vaccines and the issues discussed at
the WHO Global Advisory Committee on Vaccine Safety (GACVS)
are also very important, as well as WHO activities related to
immunization policy. In June 2019, the WHO GACVS set “six initial
strategic priorities (which) are: systems and integration; equity and
access; fragility and emergencies; values and ownership; research
and innovation; and sustainability and accountability” (https://
www.who.int/vaccine_safety/committee/reports/Jun_2019/en/).
Of importance to the report herein are their priorities on research
and innovation and on fragility and emergencies.
Dr Knezevic emphasized the importance of the present
consultation that is the last step in terms of the face-to-face
consultation on evaluating quality, safety, and efficacy of DNA
vaccines, involving regulators, manufacturers, and other experts in
this field. Representatives of several Collaborating Centers for
biological standardization are also part of the consultation, as well
as representatives of other institutions that are playing an
important role in this field.
Dr Hye-Na Kang (WHO HQ, Switzerland) provided the back-
ground to the development of the guidelines and to the
organization of this consultation. She reviewed the recommenda-
tions from the 17th meeting of ICDRA1 and the procedure of
drafting guidelines by the WHO drafting group that consisted of
Drs. Margaret A. Liu, Heidi Meyer, Edwin Nkansah, Keith Peden,
Rebecca Sheets, and WHO secretariat Hye-Na Kang. In response
to the request of the ICDRA, a drafting group prepared the first
draft of document and released it for public consultation after a
series of teleconferences (https://www.who.int/biologicals/
WHO_DNA_vaccine_HK_26_July_2019.pdf). The objective of
the informal consultation (December 2019) was to reach a
consensus on the regulatory principles of the draft guidelines,
discuss and identify any pending or critical issues such that an
improved second draft can be prepared for the final round of
public consultation, and adoption by the WHO ECBS in
October 2020.
UPDATES ON DNA VACCINE DEVELOPMENT
Several researchers in the field of plasmid DNA vaccines presented
data on the current status of their development. There continues
to be great interest by international groups on the promise of
plasmid DNA vaccines as a platform technology for the rapid and
facile development of vaccines to prevent outbreaks and
pandemics. Dr. David Kaslow (PATH, USA) representing the WHO
Product Development for Vaccines Advisory Committee (PDVAC)
reviewed the advantages of DNA vaccines as a platform
technology and how they fit into the objectives and goals of
the PDVAC. He pointed out that the guideline revision may need
to reflect the potential different purposes of a DNA vaccine—i.e.,
the use for routine immunization vs. the use for an outbreak
setting. It will be important that DNA vaccines become available
for the purposes of routine immunization if they are to be truly
available in the case of outbreak response. He also raised some
potential issues surrounding the need for a specific device for
vaccine delivery, especially in the outbreak setting, when the
supply may be limited and the cost-of-goods may not be
favorable. In preparation for such situations, current device
designs should be adapted for ease of use, and deployment in
the setting of low- and middle-income countries (LMICs), as well as
meet WHO programmatic suitability criteria for routine use. Dr.
Kaslow also raised the issue of the need for more information on
developmental toxicology for DNA vaccines to support their use in
the setting of maternal immunization, including in breast-feeding
women. These data are needed to pave the way for outbreak
responses as pregnant women often belong to the group at
highest risk for serious complications.
Dr. Nick Jackson (Coalition for Epidemic Preparedness and
Innovation (CEPI), Norway) explained the role of the CEPI and their
interest in plasmid DNA vaccines as a platform technology to
achieve their mission. They target certain pathogens in their
funding program, including Lassa virus, Middle East Respiratory
Syndrome Coronavirus (MERS-CoV), Nipah virus, Rift Valley Fever
virus, Chikungunya virus, and “Disease ‘X’” (a hypothetical
template for an emerging disease of the future). A MERS-CoV
plasmid DNA vaccine candidate has advanced into phase 1 clinical
trials with promising results. They plan to initiate a phase 2 study
in mid-2020. A Lassa virus candidate vaccine has also advanced
into a phase 1 clinical trial.
Dr. Ami Patel (The Wistar Institute, USA) discussed many
advantages of plasmid DNA vaccines and gave an update on a
therapeutic Human Papilloma Virus vaccine candidate delivered in
conjunction with an electroporation device. This vaccine candi-
date has also completed phase 2b pilot efficacy testing against
cervical cancer, with very interesting results of 40–45% impact on
endpoints, such as regression from cervical intraepithelial
neoplasia (CIN) 2/3 to CIN 1, regression to normal, and clearance
of evidence of infection4. A phase 3 study of this candidate
opened in 2017. This candidate is also being studied in head and
neck cancer5. Her team is also involved in development of Ebola,
MERS-CoV, and Zika plasmid DNA vaccine candidates. In the case
of Zika, her team was able to advance to the clinic with the
candidate plasmid DNA vaccine rapidly (7 months) largely
because of not needing to repeat nonclinical toxicology studies
on their platform technology6. Instead, decisions were made on
the basis of existing nonclinical and clinical data for the platform,
which predict safe starting doses and dose regimens, as well as
expected reactogenicity for the platform. Finally, she presented
her work on expressing monoclonal antibodies (mAb) in the
plasmid DNA system. Their anti-Zika candidate mAb has advanced
to the clinic, as well.
An update was given by Dr. Julie Ledgerwood (NIH, USA) on a
plasmid DNA vaccine candidate that had proceeded as far as an
international phase 2b (pilot efficacy) study against Zika virus.
While safety was demonstrated, the changing epidemiology in the
face of a waning epidemic meant that too few cases of Zika were
seen to evaluate efficacy; however, samples are still being
analyzed and further cases may yet be identified. Importantly,
because of their platform and earlier nonclinical and clinical work
on a West Nile Virus plasmid DNA vaccine candidate, their Zika
vaccine candidate was able to proceed to phase 1 in 3.25 months,
in large measure because additional nonclinical toxicology studies
were not required, abbreviating not only the nonclinical program,
but the overall time-to-clinic. As with Dr. Patel’s team’s vaccine
candidate, decisions were based on the existing database of
nonclinical and clinical experience with the platform. Early entry
into phase 1 permitted advancement to phase 2b even as the
outbreak was ongoing. Unfortunately, this was still not rapid
enough to capture sufficient efficacy data to support near-term
licensure of the vaccine candidate7. She also presented data on
studies performed earlier by her institute, in which plasmid DNA
vaccine candidates for Ebola and Marburg were among the first
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plasmid DNA vaccines tested in Africa, demonstrating feasibility of
testing these vaccines delivered by devices other than needle-
and-syringe in LMIC settings8.
PRINCIPLES FOR EVALUATING OF PLASMID DNA VACCINES
Plasmid DNA vaccines may be viewed as a platform technology in
which only the antigen gene has been changed from one vaccine
to another based on the same DNA plasmid backbone. For a given
manufacturer, the manufacturing and controls may vary little
between plasmid DNA vaccines they manufacture. Control
measures are likely highly similar even between manufacturers.
Therefore, the guidelines on plasmid DNA vaccines, though not
specific to a particular vaccine, can be written so as to be generally
applicable with part A, the quality section of the guidelines. In
addition, although part B, nonclinical and part C, clinical sections
will be consistent with the general guidelines on these topics,
there are a few additional topic areas of relevance to plasmid DNA
vaccines discussed in these guidelines9–11.
Many of the concerns that harken back to the beginnings of use
of plasmid DNA vaccines, two decades ago, have been deleted
from the guidelines as nonclinical and clinical evidence from
various vaccine candidates over the intervening time have
alleviated those concerns. The current generation of DNA vaccines
made from bacteria are produced biologically and are considered
to be a biological product. While the plasmid is generated by
recombinant DNA technology, it should be clarified that a plasmid
DNA vaccine itself is not an organism; thus, it is not a genetically
modified organism per se, nor is it a gene-transfer or gene-therapy
product, as it is not expected to persist and permanently “mark”
the recipient. There is a wealth of evidence that DNA vaccines to
date do not persist or even biodistribute throughout the body of
Table 1. The summary of major proposed changes in the revision of the draft guidelines for assuring the quality, safety, and efficacy of plasmid DNA
vaccines.
Sections for revision Proposed changes
Title of the document Add “plasmid” to the title.
Likewise, it was agreed to refer to DNA vaccines as plasmid DNA vaccines rather than DNA plasmid
vaccines.
Terminology Provide the definitions of adjuvant and candidate vaccine to align with the relevant WHO guidelines.
Scope Plasmid DNA expressing prophylactic monoclonal antibodies were outside of scope, but that like some
immunotherapeutics based on plasmid DNA, that the quality (part A) section may have applicability to
this product class, though parts B (nonclinical) and C (clinical) are unlikely to apply.
Introduction Add a few more of the advantages of plasmid DNA vaccines.
Part A, manufacturing and control • Definition: the International Non-Proprietary Names conventions would apply to DNA vaccines.
• General manufacturing guidelines: to clarify some language around potential for carryover or
cross-contamination in multiuse facilities.
• Source, history, and generation of the host cell and plasmid: to discuss the potential use of novel
strains or species of bacteria, and to reflect more currently the means of assessing and ensuring
genetic stability of the plasmid DNA construct.
• Characterization of the bulk purified plasmid: clarification on characterizing the mode- or
mechanism-of-action of the vaccine, including immunomodulatory elements.
• Consistency of manufacturing: clarification to reflect that this part is not referring to clinical studies,
but to timing of manufacturing assessments of consistency.
• Manufacture and control of the final formulated vaccine: a subsection needed to be added to discuss
measuring strength, dose, or content of the vaccine.
• Potency: to change some language, as mentioned above, to reflect that potency might be measured
by content and percentage supercoiling rather than use of a bioassay. Further clarity was given to
measuring the expression by mRNA rather than protein production.
• Safety, including sterility and endotoxin testing: to update to reference the monocyte activation test
and to include the 3Rs concept.
Part B, nonclinical evaluation • This section was considered to be generally satisfactory, though the need for more references that
support the abbreviation of nonclinical programs would be useful to include for regulators in
countries that have limited experience with this product type to date. Several references in this regard
will be added.
• Furthermore, some changes in part C made it apparent that further discussion was needed in part B
on the subject of the existing database of biodistribution data showing limited distribution and rapid
degradation outside the injection site, which assuage historical concerns about germ-line
involvement or genetic transfer. Likewise, a need to acknowledge the current evidence gap in
developmental toxicology for DNA vaccines was raised.
Part C, clinical evaluation • It was agreed that this section required some additions and modifications.
• Some language about the device/vaccine co-development should be included. The topics needed to
be added included post-marketing surveillance issues, choice of control group (with or without use of
device), and protocol/labeling language.
• Further, an issue that seemed to have some potential to complicate or confuse safety evaluations was
the timing of adverse events, following boost doses in heterologous prime-boost regimens and
whether to attribute them to the prime or the boost.
Part D, guidelines for national regulatory
authorities
• Language in part D, two official release and certification needs to be further examined since it is likely
that licensing of a new plasmid DNA vaccine will be reflected in a product/disease-specific WHO
guideline at the time of such. Therefore, it might not be accurate to say the vaccine lot would only be
released if it fulfilled the part A, quality section of this broad DNA vaccine guideline.
• Two appendices related to part D may need to be added to the guidelines.
– Model summary protocol for the manufacturing and control of DNA vaccines.
– Model national regulatory authority lot release certificate for DNA vaccines.
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the vaccine when delivered parenterally into muscle, subcuta-
neous tissue, or various dermal layers.
In addition, development of plasmid DNA vaccines for routine
use may lead to rapid and ready implementation of new vaccines
for emerging diseases even in the face of an emergency setting.
Once the platform technology is proven safe and efficacious for
one or more diseases, a novel vaccine candidate based on the
same technology but replacing only the antigen encoded to
match the emerging disease could permit rapid manufacturing,
reduced (abbreviated) or waived requirements for nonclinical
toxicology, and rapid entry into clinical testing. Rapid entry into
the clinic has already been shown with two plasmid DNA vaccine
candidates against Zika described above. Thus, proof-of-concept
has precedent.
DISCUSSION ON THE DRAFT GUIDELINES
This session was dedicated to reviewing the draft guidelines in
response to the public consultation. The discussion was led by
Dr. Rebecca Sheets providing a summary of comments received
from the first round of public consultation and main issues to be
discussed at this meeting. Most of these comments were accepted
and the changes made. Rejected comments were few, such as a
suggestion to follow the ICH structure rather than the WHO
standard. However, three topics remained for discussion by the
consultants at the meeting. The first of these was surrounding
several comments received on the discussion of potency
assessment of multi-plasmid-containing vaccines. The second
topic was about the appendix on heterologous prime-boost
included in the current draft document. Several comments were
made to delete the appendix as the information was included in
the body of the guideline. The third topic was on a comment
given to put more emphasis on the delivery device discussion.
The discussion on potency of multi-plasmid-containing vaccines
led to a decision to clarify the discussion in the guideline for the
rationale why this might need to be done at the individual bulk
stage instead of in the final product. However, this discussion led
to a more important and in-depth look at how potency is being
assessed currently. Most vaccine candidates are moving forward
into the clinical development without a bioassay, but simply
measuring content (quantity—the basis for dosing) and percent
supercoiled form of plasmid (a quality measure that should
correlate with potency in vivo). This led to the discussion of
revisions to the potency section itself. The appendix on
heterologous prime-boost was agreed to be deleted. The
discussion on the delivery device led to agreement that the
information already in the general principles was mostly adequate,
but that further emphasis on the labeling of what some
jurisdictions might consider to be a combination product. It was
also agreed that further discussion about the device in part C
(clinical) would add further clarity to the guidelines.
During the consultation, several suggestions for amendment of
the current draft document were made in order to reaffirm, clarify,
and provide further guidance on specific issues. These are
summarized in Table 1.
CONCLUSION AND WAY FORWARD
● The development of guidelines was welcomed and applauded
by stakeholders.
● Participants agreed that the guidelines incorporate sound
scientific evaluation principles consistent with international
initiatives and would promote regulatory convergence.
● It might be necessary for WHO to assist NRAs in implementing
the principles of the guidelines into their regulatory practices.
● Due to rapid technological advances in DNA vaccine devel-
opment, it was proposed that there should be more frequent
updating of these guidelines.
● WHO support to develop guidelines on regulatory evaluation
of vaccines for PHE uses, as well as of combination products
was requested.
● It was agreed that the guidelines be revised based on the
comments received. Following revision and another round of
public consultation, the document will be discussed at the
meeting of WHO ECBS in October 2020 for adoption.
● A need for facilitating implementation of updated WHO
guidelines for evaluation of DNA vaccines was identified as an
activity that would help NRAs in WHO members states to
establish and/or update national guidance for DNA vaccines.
● The consultation also recognized that development of RNA-
based vaccines requires WHO action. It was proposed to
consider preparation of a State of the Art Paper on the
evaluation of RNA-based vaccines (Table 1). It was clear that
the scientific evidence for these vaccines is limited and more
data will most likely become available in coming years (Table 1).
Nevertheless, the importance of WHO leadership in this area
was identified as one of the follow-up actions beyond the
revision of WHO guidelines for evaluation of DNA vaccines
(Table 1).
Reporting summary
Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
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